2 active not recruiting, 2 completed, 2 recruiting, 1 not yet recruiting. 7 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Active not recruiting 2, Completed 2, Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 6 | Active not recruiting 2, Completed 1, Recruiting 1, Terminated 1, Withdrawn 1 |
Follow Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: new trials by email Literature Review of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified trials Research Report on Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-07-09 |
| Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas Anti-CD30/CD16A Monoclonal Antibody AFM13, Cyclophosphamide, Fludarabine - Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 45 | 2020-07-18 | 2026-09-30 |
| Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma Brentuximab Vedotin, Pembrolizumab - Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 2 | Withdrawn | Northwestern University | 2020-03-01 | 2023-10-10 | |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas Pembrolizumab, Pralatrexate - Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 13 | 2019-02-04 | 2026-05-26 |
| Study of Pembrolizumab (MK-3475) in Combination With Romidepsin Pembrolizumab, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 39 | 2017-11-14 | 2026-09-30 |
| Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Laboratory Biomarker Analysis, Nivolumab - Blastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma | Phase 2 | Terminated | Mayo Clinic | 12 | 2017-05-17 | 2020-04-21 |
| A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm | Phase 1 | Recruiting | Mayo Clinic | 99 | 2017-04-04 | 2026-06-10 |
| Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma Durvalumab, Laboratory Biomarker Analysis, Lenalidomide - Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 78 | 2017-03-08 | 2026-07-31 |
| Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma Carboplatin, Etoposide, Ifosfamide - Mycosis Fungoides, Recurrent Anaplastic Large Cell Lymphoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 22 | 2012-10-29 | 2018-09-19 |
Lymphoma, T-Cell (9) · Lymphoma, Large-Cell, Anaplastic (7) · Mycosis Fungoides (7) · Immunoblastic Lymphadenopathy (6) · Enteropathy-Associated T-Cell Lymphoma (5) · Lymphoma, T-Cell, Cutaneous (3) · Subcutaneous panniculitis-like T-cell lymphoma (3) · Lymphoma, B-Cell (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · HTLV-I Infections (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Follicular (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1)
Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphatic Diseases (9) · Lymphoma (9) · Lymphoma, Non-Hodgkin (9) · Lymphoproliferative Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Lymphadenopathy (6) · Lymphoma, T-Cell, Cutaneous (4) · Hematologic Diseases (2) · Leukemia (2) · Blood Protein Disorders (1) · Bone Marrow Diseases (1)
pembrolizumab (3) · 10-propargyl-10-deazaaminopterin (2) · Cyclophosphamide (2) · Depsipeptides (2) · Disulfides (2) · Immunoglobulin G (2) · Lactones (2) · Magnetic Resonance Spectroscopy (2) · Nivolumab (2) · Specimen Handling (2) · romidepsin (2) · AFM13 (1) · Azacitidine (1) · Biopsy (1) · Brentuximab Vedotin (1)
City of Hope Medical Center (3) · M.D. Anderson Cancer Center (3) · Mayo Clinic (2) · Northwestern University (1)
United States (9)
Alex F Herrera (1) · Christiane Querfeld, MD (1) · Christina Poh (1) · Jonathan Moreira, MD (1) · Joselle Cook, M.B.B.S. (1) · Michelle Fanale (1) · Nora Bennani, M.D. (1) · Stephen Ansell (1) · Swaminathan P Iyer, MD (1) · Yago L Nieto (1)
PMID 29622656, PMID 32632956, PMID 35175355, PMID 35750419, PMID 36898933, PMID 39951620, PMID 40186077
P30CA015083 (1), P30CA016672 (1), P30CA033572 (1), P30CA060553 (1), P50CA186781 (1), R01CA229510 (1), R01CA262613 (1)